IL29 Protein (AA 23-200)
Our Local Distributor
北京 101111
Quick Overview for IL29 Protein (AA 23-200) (ABIN2667435)
抗原
See all IL29 蛋白蛋白类型
生物活性
宿主
资源
应用范围
纯度
-
-
产品特性
- AA 23-200
-
内毒素水平
-
Less than 0.1 ng per μg of protein.
-
-
Interleukin 29 (IL29) (AA 22-200) protein (His tag)
IL29 宿主: 人 宿主: 大肠杆菌（E. Coli） Recombinant Greater than 90 % as determined by SDS-PAGE. WB, ELISA
Interleukin 29 (IL29) (AA 20-200) protein (His tag)IL29 宿主: 人 宿主: Baculovirus infected Insect Cells Recombinant > 90 % SDS
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
说明
-
Biological activity: ED50 = 0.2 - 0.5 ng/ml, corresponding to a specific activity of 2.0 x 106 - 5.0 x 106 units/mg, as measured by its ability to activate STAT phosphorylation in an ISRE Luciferase Reporter Assay using human colon carcinoma COLO205 cells.
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
溶解方式
- For maximum results, quick spin vial prior to opening. Reconstitute in water to a concentration of 0.1-1.0 mg/mL. Do not vortex. It is recommended to further dilute in a buffer, such as 5 % Trehalose, and store working aliquots at -20 °C to -80 °C.
-
缓冲液
- Lyophilized, carrier-free.
-
注意事项
- Avoid repeated freeze/thaw cycles.
-
储存条件
- -20 °C
-
储存方法
- Unopened vial can be stored at -20°C or -70°C.
-
-
- IL29 (Interleukin 29 (IL29))
-
别名
- IFN-1
-
背景
- IFN-λ1, also known as IL-29, is a member of the type III interferon (IFN) family. Type III interferons, including IFN-λ1, IFN-λ2 and IFN-λ3, are produced upon virus infection and are functionally similar to type I interferon (IFN-α/β). IFN-λ binds to a heterodimeric receptor composed of the IFN-λ receptor 1 (IFNLR1) and the interleukin-10 receptor 2 (IL-10R2), subsequently tranducing signal through the JAK-STAT pathway and leading to transactivation of various IFN-stimulated genes (ISGs). IFN-λ has been demonstrated to mediate an antiviral immune response against several viruses, such as hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). In contrast to type I or type II interferons, IFN-λ receptor is expressed preferentially on epithelial-like cells and some immune cells. Because the response to IFN-λ is highly restricted to certain cell types, IFN-λ is considered a potential therapuetic agent for the treatment of viral diseases with less side effects when compared with type I interferon.
-
分子量
- The 178 amino acid recombinant protein has a predicted molecular mass of approximately 19.8 kDa. The predicted N-terminal amino acid is Pro.
抗原
-
